Redeye comments on the much-awaited news from Tessin, which has signed a letter of intent with a Eur...
ExpreS2ion Biotechnologies gör framsteg i processen att inleda studier på människa med bröstcancerva...
Redeye comments on ChromoGenics Q1 2024 report. Sales came in lower than our estimate due to the con...
Redeye gives its initial comments on the news flow from Fragbite Group earlier this morning, where F...
Calliditas delivers a positive surprise in patient enrolment (18% above our expectations) and new su...
23% y-o-y ARR growth in Q1, adj. EBITDA of DKK -3.7m "One-off" headwinds in Q1 means unchanged FY'24...
Flowscape ökade rörelseresultatet under det första kvartalet och orderingången stärktes, vilket är l...
Redeye saw a sales development that was stronger than expected.
Fastighetsbolaget Trianon uppvisade hyresintäkter om 185,4 (183,2) miljoner kronor under det första ...
Redeye comments on Northbaze Q1 2024 report. EBITDA margin was good.
Redeye provides a short comment on Ortoma’s Q1 report this morning.
Redeye comments on Embracer’s Q4-report which saw lower topline than expected while adjusted EBIT wa...
Redeye updates on Better Collective following Q1-results which were largely in line with expectation...
Positive growth outlook for margin-accretive Water segment.
CEO Daniel Krook emphasised the increased growth focus Improved growth in '24e on price hikes and a ...
Expect continued M&A, mainly in Germany 6% adj. EBITA CAGR '23-'26e, M&A to support 10% growth 12-9x...
Redeye makes nothing more than minor short-term estimate changes following Acconeer's Q1 report, mea...
Redeye notes that a new German clinical study has been published, presenting the improvement the Nev...
Redeye resumes its coverage and updates its view on BeammWave after BeammWave concluded its right is...
Redeye comments on the critical financial situation of Amniotics and the rejection of the acquisitio...
